Drug intelligence / Profile preview

PT601

Development stage: Preclinical
Lead developer: ESSA Pharma
Modality: Small Molecules

Overview

PT601 is a novel small molecule therapy being developed by ESSA Pharma, a clinical-stage company based in Vancouver, Canada, for the treatment of prostate cancer. The drug is part of ESSA's clinical program. In the second half of 2020, Pfizer made a non-controlling equity investment in ESSA Pharma to support its pipeline and provide access to Pfizer's scientific resources.

Beyond the preview

Go deeper on PT601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PT601.

Explore the full profile